You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(11.1)︱復星醫藥控股子公司Gland Pharma擬在印度證交所和孟買證交所上市 合景泰富10月預售額升123.6%至101.28億元
格隆匯 11-01 23:12

【業績預告】

永義國際(01218.HK)預期中期錄得淨虧損超1.40億港元

飛霓控股(08480.HK)預計前9月業績由盈轉虧

凱順控股(08203.HK)預期前9月將錄得虧損

華夏能源控股(08009.HK)預期中期淨虧損同比大幅增加

寶聯控股(08201.HK)預計一季度純利減少90%

美固科技控股(08349.HK)前三季度純利大幅預增

利記(00637.HK)料中期錄得淨虧損

太興置業(00277.HK)預期中期業績盈轉虧

廣澤國際發展(00989.HK)預期中期業績盈轉虧至不低於6億元

高雅光學(00907.HK)預計年度虧損顯著增長

冠忠巴士集團(00306.HK)預計中期業績由盈轉虧

【財務數據】

北京京客隆(00814.HK)前9月歸母淨利潤增長11.83%至4446萬元

ISP GLOBAL(08487.HK)第一財季淨利同比增逾7倍至22.97萬坡元

正通汽車(01728.HK):正通聯合前三季度淨利減25.29%至8.51億元

【運營數據】

富力地產(02777.HK):10月權益合約銷售額同比增長62% 環比增24%

合景泰富集團(01813.HK)10月預售額同比增123.6%至101.28億元

恆興黃金(02303.HK):金山金礦第三季度產金增長4.3%至2.48萬盎司

【重大事項】

復星醫藥(02196.HK):控股子公司Gland Pharma擬在印度證交所和孟買證交所上市

百濟神州(06160.HK)與安進達成全球戰略合作,全球生物製藥領域金額最大股權投資

石藥集團(01093.HK):降壓藥馬來酸依那普利片通過一致性評價

石藥集團(01093.HK):抗感染藥物鹽酸克林黴素膠囊通過一致性評價

石藥集團(01093.HK):抗感染藥物頭孢氨苄膠囊通過一致性評價

因無法按時更新財務數據 君實生物-B(01877.HK)中止科創板上市申請審核程序

招商銀行(03968.HK):招銀理財獲准開業

中國能源建設(03996.HK)附屬企業前三季度獲1059項專利授權

中聯重科(01157.HK):中聯重機擬在蕪湖打造一個高端智能農機制造基地

白雲山(00874.HK)子公司星羣藥業收到42個藥品再註冊批件

瑞安房地產(00272.HK)斥資18.6億元成功投得上海普陀區地塊

復星醫藥(02196.HK)子公司禪城醫院向深圳復星健康注資1040.8萬元持股51%

滔搏(06110.HK)1.3億股超額配股權獲行使 穩定價格期結束

復星旅遊文化(01992.HK)擬1100萬英鎊向Thomas Cook Groupplc收購知識產權資產

東陽光藥(01558.HK)授權九州通磷酸奧司他韋中國內地獨家總代理權

【增減持】

贛鋒鋰業(01772.HK)獲朱雀基金增持57.58萬股

海天國際(01882.HK)獲Schroders增持82.8萬股

青島啤酒股份(00168.HK)遭摩根大通減持132.47萬股

紅星美凱龍(01528.HK)多名高管已合計增持10萬股公司A股

【回購註銷】

中國平安(02318.HK)已累計耗資50億元回購5759.46萬股A股

澳洲成峯高教(01752.HK)11月1日耗資6.16萬港元回購21萬股

【增發供股】

藥明生物(02269.HK)配售4650萬股一級配售股份 淨籌39.29億港元

華潤置地(01109.HK)完成先舊後新配售2億股 淨籌67.2億港元

【債務融資】

建業地產(00832.HK)發行2億美元優先票據

【股權激勵】

貓眼娛樂(01896.HK)授出48.02萬份購股權及72.92萬份受限制股份單位

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account